Core Viewpoint - The announcement indicates a significant change in the shareholding structure of Guofang Co., Ltd. due to a court ruling leading to a judicial auction of shares held by certain individuals [1] Group 1: Shareholding Changes - The court ruling resulted in the judicial auction of 22,167,585 shares, representing 4.23% of the total share capital of Guofang Co., Ltd. [1] - Following this transaction, the combined shareholding of Zhu Rongjuan, Peng Tao, Guangxi Guofang Investment Group Co., Ltd., and Yao Fangyuan decreased from 10.72% to 6.49% [1] - Zhu Rongjuan's shareholding dropped from 7.57% to 4.01%, while Peng Tao's shareholding decreased from 0.66% to 0% [1] Group 2: Control and Ownership - Despite the reduction in shareholding percentages, the controlling shareholder and actual controller of the company remain unchanged [1]

北海国发川山生物股份有限公司 简式权益变动报告书 上市公司名称：北海国发川山生物股份有限公司 股票上市地点：上海证券交易所 股票简称： 国发股份 股票代码： 600538 信息披露义务人：朱蓉娟 住所：南宁市西乡塘区大学东路103号 通讯地址：广西南宁市青秀区金湖北路52-1号东方曼哈顿2402室 信息披露义务人：彭韬 住所：南宁市西乡塘区火炬路11号802室 通讯地址：广西南宁市青秀区金湖北路52-1号东方曼哈顿2402室 1、信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司收购管理办法》《公开发行证券公司信息披露内容与格式准则第 15 号——权益变动报告书》及相关的法律、法规编制本报告书。 2、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 3、依据《证券法》《上市公司收购管理办法》《15 号准则》的规定，本报 告书已全面披露了信息披露义务人在北海国发川山生物股份有限公司中拥有权 益的股份变动情况；截至本报告书签署日，除本报告书披露的信息外，上述信 息披露义务人没有通过任何其他方式增加或减少其在北海国 ...

证券代码：600538 证券简称：国发股份 公告编号：临 2026-001 北海国发川山生物股份有限公司 关于大股东及一致行动人部分股份被司法拍卖完成过户 暨权益变动的提示性公告 投资者及其一致行动人（朱蓉娟、彭韬、广西国发投资集团有限公司、姚芳媛）保 证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ●公司大股东朱蓉娟、彭韬合计持有的公司 22,167,585 股无限售流通股股 票（占公司总股本的比例为 4.23%）被司法拍卖非交易过户至墨江县昌宏矿业有 限责任公司名下。本次权益变动前后，公司大股东朱蓉娟及一致行动人持有公司 股份的比例由 10.72%下降至 6.49%； ●本次权益变动系大股东及一致行动人所持公司股份被司法拍卖过户被动 减持所致，不触及强制要约收购义务，本次权益变动不涉及违反已作出的承诺、 意向、计划的情况。 广西壮族自治区南宁市西乡塘区人民法院 2025 年 11 月 25 日 10 时至 2025 年 11 月 26 日 12:10 对公司大股东朱蓉娟及一致行动人彭韬合计持有的 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

证券日报网讯12月30日，国发股份（600538）发布公告称，天健会计师事务所(特殊普通合伙)作为公司 2025年度财务报表和2025年末财务报告内部控制审计机构，原委派张恩学先生、李敬女士作为2025年度 财务报表审计报告和2025年末财务报告内部控制审计报告的签字注册会计师。由于内部工作调整，现委 派赵娇女士、周黎先生接替张恩学先生、李敬女士作为签字注册会计师。变更后的签字注册会计师为赵 娇女士、周黎先生。 ...

证券代码：600538 证券简称：国发股份 公告编号：临2025-058 北海国发川山生物股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北海国发川山生物股份有限公司（以下简称"公司"）于2025年 4月18日召开的第十一届董事会第十四次会议审议通过了《关于续聘 2025年度财务审计机构和内控审计机构的议案》，同意续聘天健会计 师事务所（特殊普通合伙）（以下简称"天健"）为公司2025年度财 务审计机构及内控审计机构，续聘期限一年。该项议案已经公司 2024年年度股东大会审议通过。 公司于近日收到天健发来的《关于变更签字注册会计师的函》。 现将相关情况公告如下： 一、签字注册会计师变更的基本情况 天健作为公司2025年度财务报表和2025年末财务报告内部控制 审计机构，原委派张恩学先生、李敬女士作为2025年度财务报表审 计报告和2025年末财务报告内部控制审计报告的签字注册会计师。 由于内部工作调整，现委派赵娇女士、周黎先生接替张恩学先生、李 敬女士作为签字注册会计师。变更后的签字注册会计师为赵娇女士、 周黎先 ...

Group 1 - The company Guofang Co., Ltd. (SH 600538) announced that its 11th Board of Directors meeting will be held on December 25, 2025, to discuss the election of the chairman and other matters [1] - For the first half of 2025, the revenue composition of Guofang Co., Ltd. is as follows: pharmaceutical distribution accounts for 62.04%, DNA consumables and testing services account for 22.16%, pharmaceutical manufacturing accounts for 8.29%, judicial identification accounts for 6.22%, and other businesses account for 1.04% [1] - The current market capitalization of Guofang Co., Ltd. is 3.3 billion yuan [2]

证券之星消息，12月25日医药商业板块较上一交易日上涨0.41%，合富中国领涨。当日上证指数报收于 3959.62，上涨0.47%。深证成指报收于13531.41，上涨0.33%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603122 | 合富中国 | 26.04 | 5.25% | 90.01万 | 22.46 乙 | | 301015 | 百洋医药 | 24.22 | 2.98% | 7.45万 | 1.80亿 | | 600538 | 国发股份 | 6.35 | 2.58% | 9.20万 | 5782.41万 | | 300937 | 药易购 | 35.16 | 2.36% | 11.03万 | 3.89亿 | | 002788 | 營荷医药 | 20.06 | 2.09% | 101.86万 | 19.77亿 | | 603716 | 塞力医疗 | 22.02 | 1.71% | 20.62万 | 4.51亿 | | 603939 | 益丰药房 | ...

证券代码：600538 证券简称：国发股份 公告编号：临 2025-057 北海国发川山生物股份有限公司 第十一届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）审议通过《关于选举第十一届董事会董事长的议案》 鉴于姜烨先生于2025年12月2日辞去公司董事及董事长职务，根据《公司章 程》的相关规定：董事长为公司的法定代表人。法定代表人辞任的，公司应当 在法定代表人辞任之日起30日内确定新的法定代表人。 根据《公司章程》第一百零九条的规定：公司董事会设董事长1名，公司可 以根据需要设副董事长。董事长和副董事长由董事会以全体董事的过半数选举 产生。 公司应选董事长1人，董事长候选人为6名（非独立董事彭韬先生、程芳才 先生、张小玮先生、吴培诚先生、尹志波先生、李勇先生），故进行差额选举。 经半数以上董事同意，选举程芳才先生（简历附后）为公司第十一届董事 会董事长。 程芳才：1987年出生，大学本科。曾任广东博士科技有限公司业务总监， 1 广东博易投资管理有限公司董事长、总经 ...

（编辑 王雪儿） 证券日报网讯 12月18日晚间，国发股份发布公告称，公司2025年第三次临时股东大会审议通过《关于 取消监事会的议案》《关于修订的议案》《关于修订的议案》等多项议案。 ...